tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

Sanofi’s Strong Financial Performance and Promising Pipeline Justify Buy Rating
RatingsSanofi’s Strong Financial Performance and Promising Pipeline Justify Buy Rating
4h ago
SNY
Sanofi reports Q1 IRFS EPS EUR 1.52 vs. EUR 0.91 last year
PremiumThe Fly
Sanofi reports Q1 IRFS EPS EUR 1.52 vs. EUR 0.91 last year
6h ago
SNY
Sanofi expects closing of Opella stake sale in Q2
PremiumThe Fly
Sanofi expects closing of Opella stake sale in Q2
6h ago
SNY
Sanofi expects FY25 business EPS growth at LDD percentage at CER
PremiumThe Fly
Sanofi expects FY25 business EPS growth at LDD percentage at CER
6h ago
SNY
Innate Pharma announces EUR 15M capital increase from Sanofi
PremiumThe Fly
Innate Pharma announces EUR 15M capital increase from Sanofi
7h ago
SNY
IPHA
Sanofi’s Strong Financial Performance and Promising R&D Pipeline Justify Buy Rating
PremiumRatingsSanofi’s Strong Financial Performance and Promising R&D Pipeline Justify Buy Rating
7h ago
SNY
Innate Pharma regains rights to Anket, announces potential Sanofi investment
Premium
The Fly
Innate Pharma regains rights to Anket, announces potential Sanofi investment
1d ago
SNY
IPHA
Trump looking at cutting drug prices to international levels, Reuters says
Premium
The Fly
Trump looking at cutting drug prices to international levels, Reuters says
2d ago
AZN
BMY
SNYNF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
SNYNF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2d ago
Regeneron, Sanofi announce FDA approval of Dupixent for CSU
PremiumThe Fly
Regeneron, Sanofi announce FDA approval of Dupixent for CSU
6d ago
SNY
REGN
Sanofi’s Promising Pipeline and Strategic Advancements Justify Buy Rating
PremiumRatings
Sanofi’s Promising Pipeline and Strategic Advancements Justify Buy Rating
7d ago
SNY
Sanofi initiated with an Outperform at BNP Paribas Exane
PremiumThe Fly
Sanofi initiated with an Outperform at BNP Paribas Exane
9d ago
SNY
Sanofi’s Strong Financial Performance and Promising Growth Prospects Earn a Buy Rating
PremiumRatingsSanofi’s Strong Financial Performance and Promising Growth Prospects Earn a Buy Rating
10d ago
SNY
Novavax price target lowered to $10 from $12 at BofA
Premium
The Fly
Novavax price target lowered to $10 from $12 at BofA
14d ago
SNY
NVAX
Trump plans to announce ‘major’ tariff on pharmaceutical imports, Reuters says
Premium
The Fly
Trump plans to announce ‘major’ tariff on pharmaceutical imports, Reuters says
15d ago
AZN
BMY
Sanofi announces publication of tolebrutinib Phase 3 data in NEJM
PremiumThe Fly
Sanofi announces publication of tolebrutinib Phase 3 data in NEJM
16d ago
SNY
IGM Biosciences downgraded to Underperform from Neutral at BofA
PremiumThe Fly
IGM Biosciences downgraded to Underperform from Neutral at BofA
16d ago
SNY
IGMS
Nurix Therapeutics announces Sanofi exclusively licensed a program
PremiumThe Fly
Nurix Therapeutics announces Sanofi exclusively licensed a program
22d ago
SNY
NRIX
Sanofi’s Strong Growth Potential: Buy Rating Backed by Attractive Valuation and Robust Pipeline
PremiumRatings
Sanofi’s Strong Growth Potential: Buy Rating Backed by Attractive Valuation and Robust Pipeline
22d ago
SNY
Sanofi treatment of immunoglobulin G4-related disease granted orphan status
PremiumThe FlySanofi treatment of immunoglobulin G4-related disease granted orphan status
23d ago
SNY
Cautious Hold Rating on Sanofi Due to Safety Concerns and Limited Growth Prospects for Qfitlia
Premium
Ratings
Cautious Hold Rating on Sanofi Due to Safety Concerns and Limited Growth Prospects for Qfitlia
24d ago
SNY
Alnylam announces FDA approval of Qfitlia for treatment of hemophilia A or B
Premium
The Fly
Alnylam announces FDA approval of Qfitlia for treatment of hemophilia A or B
27d ago
SNY
ALNY

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >